Discovery of COVID-19 Inhibitors Targeting the SARS-CoV-2 Nsp13 Helicase
August 2020
in “
bioRxiv (Cold Spring Harbor Laboratory)
”
Studysummary This study suggests that two approved drugs may inhibit the SARS-CoV-2 helicase based on significant activity in laboratory models, offering hope for potential COVID-19 treatments.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
In this study, researchers focused on the SARS-CoV2 helicase (Nsp13), a critical and conserved protein for viral replication, to identify potential COVID-19 inhibitors. They used homology modeling and molecular dynamics to create structural models of the helicase and conducted virtual screening of approximately 970,000 chemical compounds targeting the ATP binding site. The study identified approved human drugs that showed significant activity in inhibiting the SARS-CoV-2 helicase, suggesting these drugs could potentially be repurposed for COVID-19 treatment.
